Robert Waltermire
Corporate Officer/Principal at MADRIGAL PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Robert Waltermire is currently the Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals, Inc. Prior to this, he worked at Venatorx Pharmaceuticals, Inc. for 32 years as the Senior Vice President-CMC.
He received his undergraduate degree from Franklin & Marshall College in 1984 and his doctorate from the University of Maryland in 1988.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-22 | 6,536 ( 0.03% ) | 2 M $ | 2024-03-30 |
Robert Waltermire active positions
| Companies | Position | Start |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-08-01 |
Former positions of Robert Waltermire
| Companies | Position | End |
|---|---|---|
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 2019-12-31 |
Training of Robert Waltermire
| Franklin & Marshall College | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
- Stock Market
- Insiders
- Robert Waltermire
